IL-13
40 programs · 38 companies
Programs
40
Companies
38
Active Trials
26
Targeting IL-13
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| Lisonaritide | Eli Lilly | Phase 3 | GBMET | |
| Sovarapivir | AbbVie | Phase 2/3 | Heart Failure | |
| Ceviderotide | Novo Nordisk | Preclinical | UCCRC | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | PsAPTSD | |
| MRN-7601 | Moderna | Phase 2 | NASHPompe | |
| Elrarapivir | Iovance | Phase 2 | HS | |
| RAR-5994 | Ultragenyx | Phase 2/3 | GA | |
| Polazumab | Editas | Phase 2/3 | PompeEpilepsy | |
| Darasacituzumab | Shanghai Junshi | Phase 2/3 | MDSIPF | |
| NIA-IIT-554 | NIAID | Phase 2/3 | Gastric Ca | |
| UCS-IIT-677 | UCSF | Phase 2/3 | Ewing Sarcoma | |
| FOR-6391 | Forma (Novo) | Preclinical | WM | |
| Nirainavolisib | Ring Ther | Phase 3 | FTDOCD | |
| Rimaglumide | Alector | Phase 2 | SCD | |
| Pexasotorasib | Omega Therapeutics | Phase 1 | WilmsMDS | |
| Terafotisoran | Compass Pathways | Phase 1 | CholangiocarcinomaNASH | |
| Nidarapivir | Compass Pathways | Phase 1/2 | FSGSNMOSD | |
| Olpafotisoran | Kinnate Bio | Phase 2 | UCT2D | |
| TRV-9080 | Trevena | Phase 1/2 | Ewing Sarcoma | |
| SEC-7279 | Second Sight | Phase 2 | MelanomaOvarian Ca | |
| Pemifutibatinib | Second Sight | Phase 2/3 | ADPKD | |
| COR-7645 | Corvus Pharma | NDA/BLA | Crohn'sBCC | |
| CLB-2823 | Caladrius Bio | Phase 2 | MDS | |
| NOR-4666 | NorthStar Med | Phase 3 | PAHADPKD | |
| VES-1701 | Vesalius | Phase 1 | MDSHS | |
| AMB-7870 | Ambys Med | Phase 3 | CMLADPKD | |
| Zanuvorutinib | Mirum Pharma | Phase 1/2 | NMOSDPsA | |
| Mirirelsin | Tarsus Pharma | Phase 1/2 | CFAS | |
| CAT-8632 | Catalyst Bio (Vertex) | Phase 2/3 | PsoriasisSLE | |
| Sovazumab | Adamas (Supernus) | Phase 1 | NMOSDADPKD | |
| Elralemzoparlimab | Turnstone Bio | Phase 1/2 | PAHPompe | |
| 488-3348 | Sawai Group | Phase 2/3 | HCCT2D | |
| NEO-620 | NeoGenomics | Phase 2/3 | NBAS | |
| OGN-5336 | Organon | Phase 1 | MigraineCKD | |
| PIE-7717 | Pierre Fabre | Preclinical | RSV | |
| NEO-1964 | Neopharma | Phase 3 | Epilepsy | |
| Rimabrutinib | Nobel Ilac | Phase 1 | MyelofibrosisAtopic Derm | |
| Pemicagene | MSN Laboratories | Approved | EpilepsyFSGS | |
| Tirasertib | Avantor | Phase 2/3 | RCCHemophilia A | |
| Teracapivasertib | Phibro Animal Health | Phase 2/3 | NMOSDEndometrial Ca |